HER2+ cancer cells were seeded in adherent condition as mentioned above and treated with haNK92 cells alone, haNK92 plus trastuzumab (equivalent of 100 nM), or haNK92 plus BiKE:E5C1 (equivalent of 100 nM), followed by cell viability measurement. Here, ERBB2 is linked to cancer.